Former unicorn Intarcia’s demise impacts Luxin Ventures



Chinese VC fund Luxin Venture Capital Group (SHA:600783) has written off to zero its entire investment in US biotech Intarcia Therapeutics following Intarcia’s second rejection from the US FDA for its long-term implant for type 2 diabetes earlier in 2020. Luxin previously invested USD 30 million in Intarcia via a funding round held in 2016, but is now writing off the entire investment and expects to report around RMB 140 million (USD 21.68 million) in losses in 2020.

The Boston, Massachusetts-based Intarcia, which was first set up in 1995, attracted over USD 1 billion in total investment for its long-term implant technology. The firm’s lead pipeline product is ITCA650, a formulation of the GLP-1 agonist exenatide designed to be steadily released inside patients over a six-month period through the firm’s matchstick-sized implants. Exenatide is usually administered daily or once per week. The investment round completed in 2016 gave Intarcia a valuation of USD 3.5 billion.

The first NDA filing was for ITCA650 was rejected by the FDA in September 2017, and a second filing met the same fate in March 2020. Intarcia has not filed for bankruptcy and aims to appeal the FDA’s decision. However, Luxin’s decision to pull its financial support from the company means that Intarcia is moving to hold an auction later this month to sell off laboratory and office equipment in an effort to remain operational.

Reference:

Related news
The Shaanxi Public Resources Trading Center released a notification in relation to the online procurement price of US major Eli Lilly’s dulaglutide.
Suzhou-based biotech Innovent Biologics (HKEX.01801) has earned two tacit clinical trial approvals for IBI362 (OXM3), a dual targeted GLP-1 and glucagon receptor agonist in licesned from Eli Lilly & Co., in August 2019.
Denmark major Novo Nordisk filed a New Drug Application (NDA) marketing for its once per week long-acting GLP-1 agonist semaglutide in China.
Colombia's National Price Commission for Pharmaceuticals and Medical Devices (CNPMDM) this week issued a notice expanding the list of drugs with controlled prices by 133 brands in 770 different formulations, and updating the price caps of 1,717 formulations, totalling 2,487 presentations in the mechanism.
Denmark’s Novo Nordisk this week received registration approval from Colombia’s National Food and Drug Surveillance Institute (INVIMA) for its antidiabetic Ozempic (semaglutide), according to GBI analysis.
Recent news
Russian firm Binnopharm Group and India's Glenmark Pharmaceuticals will collaborate on the localized production of the antiviral drug favipiravir in Russia.
A Phase III clinical trial (CT) evaluating Janssen’s HIV vaccine candidate was recently picked up in Argentina after the National Administration of Drugs, Food and Medical Technology (ANMAT) last year temporarily suspended all preventive studies that were not related to COVID-19.
Suzhou-based circulating tumor cells (CTC) specialist Junhui Biotech Co., Ltd struck a strategic partnership with compatriot firm BGI Group (XSHE:300676) subsidiary MGI Tech.
Beijing-based EdiGene Inc., announced an approval nod from the Center for Drug Evaluation (CDE) to initiate a clinical study for ET-01, a CRISPR/Cas 9 gene-editing therapeutic candidate for patients with transfusion dependent β-thalassemia.
Brazil’s Congress last week announced a bill that proposes tax exemptions for drug makers that donate their products to organizations deemed of public interest by the National Health Surveillance Agency (ANVISA).
India’s Bharat Biotech and Brazilian pharmaceutical Precisa Medicamentos last week signed an agreement to supply the former’s SARS-CoV-2 vaccine Covaxin in Brazil, prioritizing the public sector.
BeiGene has a new partner for global development of its programmed death-1 (PD-1) candidate tislelizumab after signing a co-development and commercialization deal with Swiss major Novartis focused on the territories of North America, Japan, EU and six other European countries.
  • 1611036123603
  • China
Analytics Snapshot


Analytics Snapshot